Liquidia Says UTC Can’t Stop Its New Lung Drug From Launching

Liquidia Corp. urged a federal judge to reject United Therapeutics Corp.’s emergency request to block the imminent launch of its inhaled lung-disease drug Yutrepia, arguing UTC faces no irreparable harm and is trying to relitigate issues already decided.

UTC delayed asserting US Patent No. 11,357,782 and failed to show it would suffer meaningful harm from Yutrepia’s entry, Liquidia said in an opposition brief filed Monday in the US District Court for the Middle District of North Carolina.

The requested temporary restraining order is UTC’s “fourth attempt, in its third federal court, to preliminarily enjoin Liquidia” from launching Yutrepia, a rival ...